ECM
UTHR icon

Everence Capital Management’s United Therapeutics UTHR Stock Holding History

Everence Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$748K Hold
1,380
– – 0.04% 315
2026
Q1 		$818K Hold
1,380
– – 0.05% 271
2025
Q4 		$672K Hold
1,380
– – 0.04% 314
2025
Q3 		$579K Hold
1,380
– – 0.03% 351
2025
Q2 		$397K Hold
1,380
– – 0.03% 454
2025
Q1 		$425K Hold
1,380
– – 0.03% 413
2024
Q4 		$487K Buy
+1,380
New +$507K 0.03% 369

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Everence Capital Management's UTHR Position: Q2 2026 in Review

Everence Capital Management held its United Therapeutics (UTHR) position steady in Q2 2026 at 1,380 shares worth $748K. The position accounts for 0.04% of the portfolio, ranked #315.

Everence Capital Management first reported a position in UTHR in Q4 2024 and has held it in 7 quarters since. The position peaked at $818K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Everence Capital Management held 1,380 shares of United Therapeutics worth $748K as of Q2 2026.
  • Everence Capital Management left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up 0.04% of Everence Capital Management's portfolio in Q2 2026, its #315 holding.
  • Everence Capital Management first reported a position in United Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Everence Capital Management's United Therapeutics position peaked at $818K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Everence Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.